No Data
No Data
No Data
No Data
No Data
Combatting The 'Bad Trip': New Research Project Seeks Solutions That Go Beyond Psychedelics
Ehave, Inc. (OTC:EHVVF) has completed the first of three planned phases of its studies with the University of Melbourne to determine the cause and possible cure for hallucinogen-persisting perception
Benzinga Real-time NewsFeb 4, 2023 01:46
Ehave Provides Progress Update on Its HPPD Study With University of Melbourne
Potential of monetizing HPPD research by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelicsMIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Eh
GlobeNewswireFeb 2, 2023 21:36
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
After a full review of healthcare provider Ehave Inc.'s (OTC:EHVVF) IND application, the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with a clinical trial assessing l
Benzinga Real-time NewsDec 17, 2022 06:06
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
Ehave study "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder" a
GlobeNewswireDec 15, 2022 21:06
Press Release: Ehave Shareholder From CEO Ben Kaplan and Corporate Update
Ehave Shareholder from CEO Ben Kaplan and Corporate Update MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in t
Dow JonesDec 7, 2022 21:07
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treat
Benzinga Real-time NewsJun 2, 2022 04:35
No Data
No Data